Main content

    Brain Tumor Clinical Trials

    Sutter Health participates in clinical trials related to Brain Tumor throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: Establishment of Human Tumor and Normal Tissue Bank for Molecular Oncological Studies at CPMCRI
    Description: Collection of human tumor and normal tissue for molecular
    studies.
    Investigator: Charles Cobbs, MD
    Eligibility: Subjects undergoing brain surgery.
    Status: Active and open to enrollment
    Location: California Pacific Medical Center
    Contact: Liliana Soroceanu, MD, PhD 415-600-1770 Email: SoroceL@cpmcri.org

    Title: Establishment of Human Tumor and Normal Tissue Bank for Molecular Oncological Studies at CPMCRI.
    Description: Collection of tumor and normal brain tissue for molecular studies.
    Investigator: Edie Zusman, MD
    Eligibility: Subjects undergoing brain surgery.
    Status: Active and open to enrollment.
    Location: Eden Medical Center
    Contact: Lorna Beccaria, RN, CCRC 510-727-8267 Email: BeccarL@sutterhealth.org

    Title: A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (Protocol 020221).
    Description:This Phase III trial is designed to evaluate the impact on disease progression and survival time, as well as safety, in patients following treatment with DCVax(R)-L, an immunotherapy treatment for GBM. The experimental therapy uses a patient's own tumor lysate and white blood cells from which precursors of the dendritic cells are isolated. The dendritic cell is the starter engine of the immune system. The white cells are then made into dendritic cells and they are educated to "teach" the immune system how to recognize brain cancer cells. Eligible patients will receive a series of injections of DCVax-L, to activate and then boost the immune response to the tumor cells.
    Investigator: Nora Wu, MD
    Eligibility: Open
    Status: SACTO.
    Location: SNI/SIMR
    Contact: Natalie Marlen, CCRC 916-453-5742
    Email: marlenn@sutterhealth.org OR wun@sutterhealth.org

    Title: A Phase II Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme (Protocol 020221).
    Description:This Phase II trial is designed to evaluate the impact on disease progression and survival time, as well as safety, in patients following treatment with DCVax(R)-L, an immunotherapy treatment for GBM. The experimental therapy uses a patient's own tumor lysate and white blood cells from which precursors of the dendritic cells are isolated. The dendritic cell is the starter engine of the immune system. The white cells are then made into dendritic cells and they are educated to "teach" the immune system how to recognize brain cancer cells. Eligible patients will receive a series of injections of DCVax-L, to activate and then boost the immune response to the tumor cells.
    Investigator: Tyler Kang, MD
    Eligibility: Open
    Status: Active and open to enrollment.
    Location: Eden Medical Center
    Contact: Lorna Beccaria, RN, CCRC, 510-727-8267, Email: BeccarL@sutterhealth.org

    > See All Neurology Clinical Trials by Condition